Known targets — ChEMBL curated mechanism
CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CHRM1CHRM2CHRM3CHRM4CHRM5
The experimentally established mechanism targets of Terodiline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.96 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.96 |
| ▸ | CACNA1C known ✓ | Q13936 | 2/20 | 0.96 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 0.96 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.96 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 0.96 |
| ▸ | CACNA1S known ✓ | Q13698 | 1/20 | 0.96 |
| ▸ | HRH1 | P35367 | 5/20 | 0.96 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.96 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.96 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.96 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.96 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.96 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terodiline SCHEMBL78908 | 0.98 | HRH1 (1.00) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| Terodiline SCHEMBL9008621 | 0.98 | HRH1 (1.00) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| Terodiline SCHEMBL121864 | 0.96 | HRH1 (0.96) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| Terodiline SCHEMBL110026 | 0.94 | HRH1 (0.93) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| Terodiline SCHEMBL8149719 | 0.93 | HRH1 (0.89) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| SCHEMBL9107533 | 0.88 | ADRA1A (0.81) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| SCHEMBL9008867 | 0.88 | ADRA1A (0.81) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| SCHEMBL9108716 | 0.88 | ADRA1A (0.81) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| SCHEMBL9008774 | 0.88 | ADRA1A (0.81) | HRH1ADRA1ASLC6A3KCNH2CHRM2 | |
| SCHEMBL9008606 | 0.88 | ADRA1A (0.81) | HRH1ADRA1ASLC6A3KCNH2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633695-B1 | SMOOTH MUSCLE SPASMOLYTIC AGENTS | BRIDGE PHARMA INC (US) | 2012-02-15 | — | — | EP | disclosed |
| EP-1633695-A4 | SMOOTH MUSCLE SPASMOLYTIC AGENTS | BRIDGE PHARMA INC (US) | 2007-12-12 | — | — | EP | disclosed |
| US-7141696-B2 | Smooth muscle spasmolytic agents | BRIDGE PHARMA, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1633695-A2 | SMOOTH MUSCLE SPASMOLYTIC AGENTS | Bridge Pharma, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004105692-A2 | SMOOTH MUSCLE SPASMOLYTIC AGENTS | BRIDGE PHARMA, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040248987-A1 | Smooth muscle spasmolytic agents | BRIDGE PHARMA, INC. | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248987-A1 | Smooth muscle spasmolytic agents | MYLK, TNNC1, MYLK2 | CHRM2 22/4885CHRM1 39/4885CACNA1C 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.